US Bancorp’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,241
| Closed | -$19.5K | – | 4138 |
|
|
2024
Q1 | $19.5K | Sell |
1,241
-103
| -8% | -$1.58K | ﹤0.01% | 3112 |
|
|
2023
Q4 | $21.7K | Sell |
1,344
-4
| -0.3% | -$51 | ﹤0.01% | 3019 |
|
|
2023
Q3 | $17.1K | Sell |
1,348
-2,076
| -61% | -$28.6K | ﹤0.01% | 2954 |
|
|
2023
Q2 | $48.2K | Sell |
3,424
-894
| -21% | -$12.8K | ﹤0.01% | 2517 |
|
|
2023
Q1 | $66.7K | Sell |
4,318
-151
| -3% | -$2.52K | ﹤0.01% | 2379 |
|
|
2022
Q4 | $73.2K | Sell |
4,469
-371
| -8% | -$6.03K | ﹤0.01% | 2334 |
|
|
2022
Q3 | $90K | Buy |
4,840
+788
| +19% | +$12.4K | ﹤0.01% | 2243 |
|
|
2022
Q2 | $53K | Buy |
4,052
+2,032
| +101% | +$22.4K | ﹤0.01% | 2548 |
|
|
2022
Q1 | $18K | Sell |
2,020
-328
| -14% | -$2.79K | ﹤0.01% | 3149 |
|
|
2021
Q4 | $23K | Buy |
2,348
+367
| +19% | +$6.9K | ﹤0.01% | 3046 |
|
|
2021
Q3 | $68K | Buy |
1,981
+366
| +23% | +$11.7K | ﹤0.01% | 2497 |
|
|
2021
Q2 | $59K | Sell |
1,615
-10,852
| -87% | -$420K | ﹤0.01% | 2593 |
|
|
2021
Q1 | $559K | Sell |
12,467
-76
| -0.6% | -$3.54K | ﹤0.01% | 1433 |
|
|
2020
Q4 | $716K | Buy |
12,543
+1,470
| +13% | +$87.1K | ﹤0.01% | 1260 |
|
|
2020
Q3 | $568K | Buy |
11,073
+8,121
| +275% | +$398K | ﹤0.01% | 1258 |
|
|
2020
Q2 | $176K | Buy |
2,952
+939
| +47% | +$50.2K | ﹤0.01% | 1821 |
|
|
2020
Q1 | $83K | Buy |
2,013
+730
| +57% | +$40.5K | ﹤0.01% | 2121 |
|
|
2019
Q4 | $80K | Buy |
1,283
+614
| +92% | +$29.2K | ﹤0.01% | 2262 |
|
|
2019
Q3 | $23K | Buy |
+669
| New | +$19.8K | ﹤0.01% | 2790 |
|
Other funds holding DCPH
US Bancorp's DCPH Position: Q2 2024 in Review
US Bancorp sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 1,241 shares — an estimated $19.5K sold.
US Bancorp first reported a position in DCPH in Q3 2019 and held it in 19 quarters. The position peaked at $716K in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- US Bancorp reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- US Bancorp sold 1,241 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $19.5K.
- US Bancorp first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 19 quarters.
- US Bancorp's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $716K in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on US Bancorp's 13F filing for Q2 2024, filed 7 Aug 2024.